-
Mashup Score: 0Sulbactam-Durlobactam Combo Outperforms Colistin in Acinetobacter baumannii Infections - 6 month(s) ago
A phase 3 trial presented at IDWeek 2023 shows that sulbactam-durlobactam (SUL-DUR) reduces mortality and improves outcomes in hospital-acquired Acinetobacter baumannii-calcoaceticus complex infections compared to colistin, offering a promising treatment option.
Source: www.infectioncontroltoday.comCategories: Infectious Disease, Latest HeadlinesTweet
-
Mashup Score: 0An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii - Nature Reviews Microbiology - 12 month(s) ago
Acinetobacterstrains have become a cause for concern — particularly among critically ill, hospitalized patients — owing to the spread of multidrug resistance and risk of epidemics. Here, the authors discuss the current knowledge of the genusAcinetobacter, with the emphasis on the clinically most important species, Acinetobacter baumannii.
Source: NatureCategories: Infectious Disease, Latest HeadlinesTweet
-
Mashup Score: 10
Take 5 minutes to catch up on Infection Control Today’s highlights for the week ending August 12.
Source: Infection Control TodayCategories: Infectious Disease, Latest HeadlinesTweet
-
Mashup Score: 0
Take 5 minutes to catch up on Infection Control Today’s highlights for the week ending August 12.
Source: Infection Control TodayCategories: Infectious Disease, Latest HeadlinesTweet
-
Mashup Score: 0
Take 5 minutes to catch up on Infection Control Today’s highlights for the week ending August 12.
Source: Infection Control TodayCategories: Infectious Disease, Latest HeadlinesTweet
-
Mashup Score: 4Comparative genomics of Acinetobacter baumannii and therapeutic bacteriophages from a patient undergoing phage therapy - Nature Communications - 2 year(s) ago
A patient with a multidrug-resistant bacterial infection was successfully treated in 2016 using phage therapy. Here, the authors sequence the genomes of the therapeutic phages and three bacterial strains isolated before and during treatment, and show that the same mutations conferring phage resistance are found in in vitro-generated mutants and in phage-insensitive strains isolated from the…
Source: NatureCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 1Comparative genomics of Acinetobacter baumannii and therapeutic bacteriophages from a patient undergoing phage therapy - Nature Communications - 2 year(s) ago
A patient with a multidrug-resistant bacterial infection was successfully treated in 2016 using phage therapy. Here, the authors sequence the genomes of the therapeutic phages and three bacterial strains isolated before and during treatment, and show that the same mutations conferring phage resistance are found in in vitro-generated mutants and in phage-insensitive strains isolated from the…
Source: NatureCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 1Managing phage therapy to help save lives - AgriLife Today - 2 year(s) ago
Study involving Texas A&M’s Center for Phage Technology shows how phages fight multidrug-resistant pathogens.
Source: AgriLife TodayCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 3
Acinetobacter species are considered dreadful pathogens for patients in the intensive care unit as they are often multidrug resistant (MDR), leading to difficult-to-treat infections and, occasionally, therapeutic dead ends. Carbapenem-resistant Acinetobacter are in the top position of “the WHO priority pathogens”, for which novel antibiotics are desperately needed. The carbapenem-resistance is…
Source: The Lancet MicrobeCategories: Infectious Disease, Latest HeadlinesTweet
-
Mashup Score: 22Structural equation modeling the “control of gut overgrowth” in the prevention of ICU-acquired Gram-negative infection - 4 year(s) ago
Conceptually, the “control of gut overgrowth” (COGO) is key in mediating prevention against infection with Gram-negative bacilli by topical antibiotic prophylaxis, a common constituent of selective digestive decontamination (SDD) regimens. However, the relative importance of the other SDD components, enteral and protocolized parenteral antibiotic prophylaxis, versus other methods of infection…
Source: Critical CareCategories: Critical Care, Latest HeadlinesTweet
Phase 3 trial at IDWeek 2023 shows SUL-DUR reduces mortality and improves outcomes in hospital-acquired Acinetobacter baumannii-calcoaceticus complex infections, offering a promising treatment option. https://t.co/UcYIEcWl9k #IDWeek2023 #colisten #acinetobacter